新型 PELC/CpG 佐剂配制的 H7N9 亚单位疫苗用重组血凝素蛋白。
Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.
机构信息
Institute of Biotechnology, National Tsing Hua University, Hsinchu, 30013, Taiwan.
Genomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
出版信息
Antiviral Res. 2017 Oct;146:213-220. doi: 10.1016/j.antiviral.2017.09.014. Epub 2017 Sep 22.
Humans infected with H7N9 avian influenza viruses can result in severe pneumonia and acute respiratory syndrome with an approximately 40% mortality rate, and there is an urgent need to develop an effective vaccine to reduce its pandemic potential. In this study, we used a novel PELC/CpG adjuvant for recombinant H7HA (rH7HA) subunit vaccine development. After immunizing BALB/c mice intramuscularly, rH7HA proteins formulated in this adjuvant instead of an alum adjuvant elicited higher IgG, hemagglutination-inhibition, and virus neutralizing antibodies in sera; induced higher numbers of H7HA-specific IFN-γ-secreting T cells and antibody secreting cells in spleen; and provided improved protection against live virus challenges. Our results indicate that rH7HA proteins formulated in PELC/CpG adjuvant can induce potent anti-H7N9 immunity that may provide useful information for H7N9 subunit vaccine development.
人感染 H7N9 禽流感病毒可导致严重肺炎和急性呼吸窘迫综合征，死亡率约为 40%，因此迫切需要开发有效的疫苗来降低其大流行的潜力。在这项研究中，我们使用了一种新型的 PELC/CpG 佐剂来开发重组 H7HA（rH7HA）亚单位疫苗。通过肌肉内免疫 BALB/c 小鼠，用这种佐剂配制的 rH7HA 蛋白而不是明矾佐剂在血清中引发了更高水平的 IgG、血凝抑制和病毒中和抗体；诱导了更多的 H7HA 特异性 IFN-γ 分泌 T 细胞和抗体分泌细胞在脾脏中；并提供了针对活病毒攻击的更好保护。我们的结果表明，用 PELC/CpG 佐剂配制的 rH7HA 蛋白可以诱导有效的抗 H7N9 免疫，这可能为 H7N9 亚单位疫苗的开发提供有用的信息。
Zotero 插件